Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network
Top Cited Papers
Open Access
- 20 September 2005
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 131 (1), 29-38
- https://doi.org/10.1111/j.1365-2141.2005.05716.x
Abstract
Mantle cell lymphoma (MCL) is a distinct lymphoma subtype with a particularly poor clinical outcome. The clinical relevance of the morphological characteristics of these tumours remains uncertain. The European MCL Network reviewed 304 cases of MCL to determine the prognostic significance of histopathological characteristics. Cytomorphological subtypes, growth pattern and markers of proliferation (mitotic and Ki‐67 indices) were analysed. In addition to the known cytological subtypes, classical (87·5%), small cell (3·6%), pleomorphic (5·9%) and blastic (2·6%), we identified new pleomorphic subgroups with mixtures of cells (classical + pleomorphic type; 1·6%) or transitions (classical/pleomorphic type; 1·6%), which, however, did not differ significantly in overall survival time. Exactly 80·5% of cases displayed a diffuse growth pattern, whereas 19·5% of cases had a nodular growth pattern, which was associated with a slightly more favourable prognosis. A high proliferation rate (mitotic or Ki‐67 indices) was associated with shorter overall survival. Cut‐off levels were defined that allowed three subgroups with different proliferation rates to be discriminated, which showed significantly different clinical outcomes (P < 0·0001). Based on this large clinicopathological study of prospective clinical trials, multivariate analysis confirmed the central prognostic role of cell proliferation and its superiority to all other histomorphological and clinical criteria.Keywords
This publication has 39 references indexed in Scilit:
- Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL NetworkBlood, 2005
- Moderate Increase of Secondary Hematologic Malignancies After Myeloablative Radiochemotherapy and Autologous Stem-Cell Transplantation in Patients With Indolent Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study GroupJournal of Clinical Oncology, 2004
- Follicular Lymphoma International Prognostic IndexBlood, 2004
- Large‐cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcomeBritish Journal of Haematology, 1996
- Mantle cell lymphoma: a clinicopathological study of 55 casesHistopathology, 1995
- The anaplastic variant of centrocytic lymphoma is marked by frequent rearrangements of the bcl‐1 gene and high proliferation indicesHistopathology, 1994
- Lymphocytic Lymphoma of Intermediate DifferentiationThe American Journal of Surgical Pathology, 1990
- Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosisHematological Oncology, 1989
- Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).Journal of Histochemistry & Cytochemistry, 1984
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981